Or­biMed-backed Pre­lude Ther­a­peu­tics rais­es $60M to tack­le re­sis­tance to can­cer treat­ments

Back in 2016 Kris Vad­di left a 12-year ca­reer at In­cyte to start his own ef­fort div­ing in­to re­sis­tance mech­a­nisms in can­cer at Pre­lude Ther­a­peu­tics. Three years lat­er, he has a first pro­gram to show for it, as well as a $60 mil­lion Se­ries B and two new re­cruits to the C-suite.

Co-led by Or­biMed and an­oth­er un­named ex­ist­ing in­vestor, the B round will pay for clin­i­cal proof-of-con­cept stud­ies of Pre­lude’s PRMT5 in­hibitor. PRMT5, or pro­tein argi­nine methyl­trans­ferase 5, is be­lieved to play a cen­tral role in sev­er­al path­ways for can­cer cell pro­lif­er­a­tion, cell cy­cle pro­gres­sion and re­sis­tance to apop­to­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.